(April 2, 2024, 2:07 PM EDT) -- WASHINGTON, D.C. — The Federal Circuit U.S. Court of Appeals on April 1 remanded a dispute over the validity of a patent directed to an injectable treatment for adult schizophrenia, with the court finding that a New Jersey federal judge’s “misunderstanding of claim scope carried throughout” her obviousness analysis....